Investor Presentaiton

Oncology Hematology Cell Therapy Immunology Cardiovascular Onureg (Hypomethylating Agent) Indication Phase/Study (IPSS-R) Low-or Intermediate Risk MDS Phase II/III - METEOROID N = 230 # of Patients Design Endpoints Part I: • Onureg 200 mg, 300 mg in Phase II + Best Supportive Care Part II: • Onureg RP3D in Phase III + Best Supportive Care ⚫ Placebo Primary: Safety & Tolerability & RP3D (Phase II) Achieved Complete Remission per IWG 2006 within 6 cycles (Phase II & III) Key Secondary: 84-day pRBC TI (Phase II & III) • Recruiting Status Projected data readout 2026 CT Identifier lli Bristol Myers Squibb | Q3 2023 Results NCT05469737 Not for Product Promotional Use 43

View entire presentation